Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus

ABSTRACT: Background and aims 6-sulfoLacNAc+ monocytes (slanMos) are a subset of nonclassical monocytes, which are considered pro-inflammatory cells in different diseases, including the autoimmune ones, such as systemic lupus erythematosus (SLE). Reduction and dysfunction of circulating nonclassical...

Full description

Autores:
Álvarez Díaz, Karen Dayanna
Losada Vanegas, Paula Ximena
Pineda Tamayo, Ricardo Antonio
Giraldo Morales, Luis Fernando
Vásquez Duque, Gloria María
Mauricio, Rojas López
Ruiz Agudelo, Esneyder
Tipo de recurso:
http://purl.org/coar/resource_type/c_5794
Fecha de publicación:
2022
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/29564
Acceso en línea:
http://hdl.handle.net/10495/29564
Palabra clave:
Autoinmunidad
Autoimmunity
Monocitos
Monocytes
Inflamación
Inflammation
Rights
openAccess
License
Atribución-NoComercial-CompartirIgual 2.5 Colombia
id UDEA2_d7f0c88b951cf04fed32326357539a97
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/29564
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus
title Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus
spellingShingle Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus
Autoinmunidad
Autoimmunity
Monocitos
Monocytes
Inflamación
Inflammation
title_short Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus
title_full Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus
title_fullStr Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus
title_full_unstemmed Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus
title_sort Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosus
dc.creator.fl_str_mv Álvarez Díaz, Karen Dayanna
Losada Vanegas, Paula Ximena
Pineda Tamayo, Ricardo Antonio
Giraldo Morales, Luis Fernando
Vásquez Duque, Gloria María
Mauricio, Rojas López
Ruiz Agudelo, Esneyder
dc.contributor.author.none.fl_str_mv Álvarez Díaz, Karen Dayanna
Losada Vanegas, Paula Ximena
Pineda Tamayo, Ricardo Antonio
Giraldo Morales, Luis Fernando
Vásquez Duque, Gloria María
Mauricio, Rojas López
Ruiz Agudelo, Esneyder
dc.contributor.conferencename.spa.fl_str_mv International Congress on Autoimmunity (13 : 11 de Junio 2022 : Atenas, Grecia)
dc.subject.decs.none.fl_str_mv Autoinmunidad
Autoimmunity
Monocitos
Monocytes
Inflamación
Inflammation
topic Autoinmunidad
Autoimmunity
Monocitos
Monocytes
Inflamación
Inflammation
description ABSTRACT: Background and aims 6-sulfoLacNAc+ monocytes (slanMos) are a subset of nonclassical monocytes, which are considered pro-inflammatory cells in different diseases, including the autoimmune ones, such as systemic lupus erythematosus (SLE). Reduction and dysfunction of circulating nonclassical monocytes and recruitment of these cells to inflammation sites in SLE patients have been previously reported by our Group. We proposed encapsulating Itacitinib into nanoparticles to inhibit the JAK-STAT pathway in SlanMo from SLE patients and other chronic inflammatory diseases. Methods Monocyte subpopulations were evaluated in SLE patients (n=10, from ARTMEDICA) and healthy controls (n=10) by flow cytometry markers (CD14, CD16, HLA-DR, and Slan). SlanMos were isolated using a commercial kit. Inhibition of the JAK-STAT pathway was evaluated with Baricitinib or Itacitinib and stimulated with IFN-ɤ. HLA-DR, CD64, and CD69, p-STAT-1, and TNF-α accumulation were determined by flow cytometry. We evaluated the specific binding of Poly-lactic-co-glycolic acid (PLGA), galactosamine-PLGA, and wheat germ agglutinin (WGA)-PLGA nanoparticles by leukocytes. Results Patients had a significantly lower number of circulating SlanMo. Itactinib had the highest inhibitory effect on the JAK-STAT pathway. Then, we will design an Itacitinib encapsulated nanoparticle to target the SlanMo. We had established that PLGA-WGA nanoparticles were uptook efficiently by monocytes compared with other leukocytes. Suggesting the potential role of these nanoparticles to target monocytes and possibly more specifically SlanMos for the treatment of SLE. Conclusions The uptake of PLGA-WGA nanoparticles by monocytes suggests the potential role of these nanoparticles to target these cells and possibly more specifically SlanMo for the treatment of SLE.
publishDate 2022
dc.date.accessioned.none.fl_str_mv 2022-07-06T16:48:18Z
dc.date.available.none.fl_str_mv 2022-07-06T16:48:18Z
dc.date.issued.none.fl_str_mv 2022
dc.type.spa.fl_str_mv info:eu-repo/semantics/conferenceObject
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_c94f
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_b1a7d7d4d402bcce
dc.type.hasversion.spa.fl_str_mv info:eu-repo/semantics/draft
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_5794
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/EC
dc.type.local.spa.fl_str_mv Documento de conferencia
format http://purl.org/coar/resource_type/c_5794
status_str draft
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10495/29564
url http://hdl.handle.net/10495/29564
dc.language.iso.spa.fl_str_mv eng
language eng
dc.rights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.*.fl_str_mv Atribución-NoComercial-CompartirIgual 2.5 Colombia
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/2.5/co/
dc.rights.accessrights.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv Atribución-NoComercial-CompartirIgual 2.5 Colombia
http://creativecommons.org/licenses/by-nc-sa/2.5/co/
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.group.spa.fl_str_mv Grupo de Inmunología Celular e Inmunogenética
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstream/10495/29564/1/AlvarezKaren_2022_Nanoparticles-Specific-Slan.pptx
https://bibliotecadigital.udea.edu.co/bitstream/10495/29564/2/AlvarezKaren_2022_Nanoparticles-Specific-Slan.pdf
https://bibliotecadigital.udea.edu.co/bitstream/10495/29564/3/license_rdf
https://bibliotecadigital.udea.edu.co/bitstream/10495/29564/4/license.txt
bitstream.checksum.fl_str_mv 64651c912d4d3f2bdc716049d4faf5b3
9414dd7308417c3116b20c9d2eb16199
e2060682c9c70d4d30c83c51448f4eed
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad de Antioquia
repository.mail.fl_str_mv andres.perez@udea.edu.co
_version_ 1812173203653525504
spelling Álvarez Díaz, Karen DayannaLosada Vanegas, Paula XimenaPineda Tamayo, Ricardo AntonioGiraldo Morales, Luis FernandoVásquez Duque, Gloria MaríaMauricio, Rojas LópezRuiz Agudelo, EsneyderInternational Congress on Autoimmunity (13 : 11 de Junio 2022 : Atenas, Grecia)2022-07-06T16:48:18Z2022-07-06T16:48:18Z2022http://hdl.handle.net/10495/29564ABSTRACT: Background and aims 6-sulfoLacNAc+ monocytes (slanMos) are a subset of nonclassical monocytes, which are considered pro-inflammatory cells in different diseases, including the autoimmune ones, such as systemic lupus erythematosus (SLE). Reduction and dysfunction of circulating nonclassical monocytes and recruitment of these cells to inflammation sites in SLE patients have been previously reported by our Group. We proposed encapsulating Itacitinib into nanoparticles to inhibit the JAK-STAT pathway in SlanMo from SLE patients and other chronic inflammatory diseases. Methods Monocyte subpopulations were evaluated in SLE patients (n=10, from ARTMEDICA) and healthy controls (n=10) by flow cytometry markers (CD14, CD16, HLA-DR, and Slan). SlanMos were isolated using a commercial kit. Inhibition of the JAK-STAT pathway was evaluated with Baricitinib or Itacitinib and stimulated with IFN-ɤ. HLA-DR, CD64, and CD69, p-STAT-1, and TNF-α accumulation were determined by flow cytometry. We evaluated the specific binding of Poly-lactic-co-glycolic acid (PLGA), galactosamine-PLGA, and wheat germ agglutinin (WGA)-PLGA nanoparticles by leukocytes. Results Patients had a significantly lower number of circulating SlanMo. Itactinib had the highest inhibitory effect on the JAK-STAT pathway. Then, we will design an Itacitinib encapsulated nanoparticle to target the SlanMo. We had established that PLGA-WGA nanoparticles were uptook efficiently by monocytes compared with other leukocytes. Suggesting the potential role of these nanoparticles to target monocytes and possibly more specifically SlanMos for the treatment of SLE. Conclusions The uptake of PLGA-WGA nanoparticles by monocytes suggests the potential role of these nanoparticles to target these cells and possibly more specifically SlanMo for the treatment of SLE.COL0008639application/pdfenginfo:eu-repo/semantics/draftinfo:eu-repo/semantics/conferenceObjecthttp://purl.org/coar/resource_type/c_5794http://purl.org/coar/resource_type/c_c94fhttps://purl.org/redcol/resource_type/ECDocumento de conferenciahttp://purl.org/coar/version/c_b1a7d7d4d402bcceinfo:eu-repo/semantics/openAccessAtribución-NoComercial-CompartirIgual 2.5 Colombiahttp://creativecommons.org/licenses/by-nc-sa/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc-sa/4.0/Nanoparticles specific for Slan+ monocytes as potential therapeutic tools in systemic lupus erythematosusGrupo de Inmunología Celular e InmunogenéticaAutoinmunidadAutoimmunityMonocitosMonocytesInflamaciónInflammation13th International Congress on AutoimmunityAtenas, Grecia2022-06-10/2022-06-13ORIGINALAlvarezKaren_2022_Nanoparticles-Specific-Slan.pptxAlvarezKaren_2022_Nanoparticles-Specific-Slan.pptxPresentaciónapplication/vnd.openxmlformats-officedocument.presentationml.presentation1885017https://bibliotecadigital.udea.edu.co/bitstream/10495/29564/1/AlvarezKaren_2022_Nanoparticles-Specific-Slan.pptx64651c912d4d3f2bdc716049d4faf5b3MD51AlvarezKaren_2022_Nanoparticles-Specific-Slan.pdfAlvarezKaren_2022_Nanoparticles-Specific-Slan.pdfResumenapplication/pdf104396https://bibliotecadigital.udea.edu.co/bitstream/10495/29564/2/AlvarezKaren_2022_Nanoparticles-Specific-Slan.pdf9414dd7308417c3116b20c9d2eb16199MD52CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81051https://bibliotecadigital.udea.edu.co/bitstream/10495/29564/3/license_rdfe2060682c9c70d4d30c83c51448f4eedMD53LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstream/10495/29564/4/license.txt8a4605be74aa9ea9d79846c1fba20a33MD5410495/29564oai:bibliotecadigital.udea.edu.co:10495/295642022-07-06 12:18:15.557Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=